Skyrizi
Entity.
- Evidence
- 25 documents · 9 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 11 Sept 2026, last seen 26 Oct 2026
- Measured
- 4% of mentions say something specific about it; the rest only name it
- As of
- 26 Oct 2026
Where this comes from
- The Clinical Trial Vanguard · 2026-10-24 · FDA Approves Subcutaneous SKYRIZI for Crohn’s Disease Induction (opens the source in a new tab)
- PR Newswire · 2026-10-17 · SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 (opens the source in a new tab)